接受免疫检查点抑制剂治疗的非小细胞肺癌软脑膜转移患者的生存情况
研究合并7个欧洲中心2012年11月至2018年7月接受免疫检查点抑制剂(ICI)治疗的晚期非小细胞肺癌(NSCLC)患者前瞻性名单,回顾性选取ICI开始前即有软脑膜转移(LM)者,按美国国家综合癌症网络(NCCN)LM预后分级分组,评估无进展生存(PFS)与总生存(OS)。1288例中19例(1.5%)有LM,ICI治疗中位PFS为2.0个月、中位OS为3.7个月;NCCN预后良好组6个月PFS率40% vs 预后不良组0%(p=0.05),OS两组无统计学显著差异。
要点
- 1288例接受ICI治疗的晚期NSCLC中19例(1.5%)在ICI开始前即有LM,73.7%合并同步脑转移。
- ICI治疗中位PFS为2.0个月、中位OS为3.7个月,6个月PFS率21.0%、12个月PFS率0%。
- 6个月PFS率NCCN预后良好组40% vs 预后不良组0%(p=0.05),OS两组无统计学显著差异。
核心结论
- 部分NSCLC伴LM患者可从ICI治疗中获益;具体而言,NCCN LM预后良好组患者可获得较长生存。
研究设计与样本
- 前瞻性收集7个欧洲中心2012年11月至2018年7月接受ICI治疗的晚期NSCLC患者名单并合并,回顾性补充数据,选取ICI开始前即有LM的患者,按NCCN LM预后分级分为良好组与不良组,评估ICI治疗下的PFS与OS。
主要发现
- 1288例中19例(1.5%)有LM,其中73.7%有同步脑转移、73.7%在ICI开始时存在神经系统症状、52.6%属NCCN LM预后良好组;42.1%患者已知PD-L1表达,其中87.5%为阳性。
- 自ICI开始中位随访13个月,中位PFS为2.0个月(95%CI 1.8-2.2),6个月PFS率21.0%、12个月PFS率0%。
- 6个月PFS率NCCN预后良好组40% vs 预后不良组0%(p=0.05);自ICI开始中位OS为3.7个月(95%CI 0.9-6.6),6个月OS率36.8%、12个月OS率21.1%,良好组与不良组间均无统计学显著差异(分别为p=0.40和p=0.56)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with non-small cell lung cancer (NSCLC) experience leptomeningeal metastases (LM) in 3-9% of cases. Because overall survival (OS) and performance status are very poor, they are mostly excluded from clinical trials. Here, we evaluated survival of patients with NSCLC having LM treated with immune checkpoint inhibitors (ICIs). METHODS: A prospectively collected list of patients with advanced NSCLC treated with ICIs between November 2012 and July 2018 in 7 European centres was merged. All patients with LM before ICI start were selected, data were retrospectively added and patients were classified according to the National Comprehensive Cancer Network (NCCN) LM prognostic classification (good/poor). Progression-free survival (PFS) and OS on ICIs were evaluated. RESULTS: Nineteen of 1288 (1.5%) patients had LM; 73.7% had synchronous brain metastases; 73.7% had neurological symptoms at the start of ICIs and 52.6% were in the NCCN LM good prognosis group. Programmed death ligand-1 (PD-L1) expression was known for 42.1% of patients (87.5% positive). Median follow-up was 13 months from the start of ICIs, and median (95% confidence interval [CI]) PFS on ICIs was 2.0 (1.8-2.2) months. Six-month PFS rate was 21.0% and was significantly higher in the NCCN good versus poor prognostic group: 40% vs 0% (p = 0.05). Twelve-month PFS rate was 0%. Median (95% CI) OS from the start of ICIs was 3.7 (0.9-6.6) months. Six-month OS rate was 36.8%, and 12-month OS rate was 21.1%; both were not statistically significantly different for the good versus poor NCCN prognostic group (p = 0.40 and p = 0.56, respectively). CONCLUSION: Some patients with NSCLC having LM do benefit from ICI treatment; specifically, those in the NCCN LM good prognosis group can obtain a long survival.
引用
- Hendriks LEL, Bootsma G, Mourlanette J, et al. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. Eur J Cancer. 2019. PMID: 31203193. doi:10.1016/j.ejca.2019.05.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。